EUVIMEDEUVIMED entdecken
Open Access

Chronic Viral Hepatitis With MASLD: Implications for Clinical and Patient‐Reported Outcomes

George Papatheodoridis, Maria Buti, Yusuf Yilmaz iD, Ming-Lung Yu iD, Mohamed El-Kassas iD, Khalid Alswat iD, Marlen Ivon Castellanos Fernandez iD, Yuichiro Eguchi iD, Ajay Duseja, Caglayan Keklikkiran iD, Saeed Hamid iD, Wah Kheong Chan und 11 weitere

Journal of Gastroenterology and Hepatology · 2026

DOI: 10.1111/jgh.70533 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Gastroenterology and Hepatology, 2026. Verfasst von George Papatheodoridis und 22 weiteren Autor:innen. Beteiligte Einrichtung: The Global NASH/MASH and Global Liver Councils, Washington, DC, USA. Hauptthemen laut MEDLINE: Patient Reported Outcome Measures, Hepatitis B, Chronic, Hepatitis C, Chronic, Fatty Liver. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: The Center for Outcomes Research for Liver Disease, Global NASH/MASH Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hepatitis B virus (HBV), hepatitis C virus (HCV), and metabolic dysfunction‐associated steatotic liver disease (MASLD) are common liver diseases. Clinical characteristics and patient‐reported outcomes (PROs) of HBV and HCV patients with/without superimposed MASLD were evaluated.

Methods

Cross‐sectional study of clinical and PRO (FACIT‐Fatigue [FACIT‐F], Chronic Liver Disease Questionnaire [CLDQ], Work Productivity and Activity Impairment [WPAI] questionnaire) data from Global Liver Registry, HBV and HCV patients. MASLD was defined as Hepatic Steatosis Index (HSI) ≥ 36 with ≥ 1 cardiometabolic risk factor (overweight, type 2 diabetes, hypertension, and hyperlipidemia).

Results

Among 4649 subjects, 2063 had HBV (48 ± 13 years; 57% male; 11% advanced fibrosis; 49% MASLD); 2586 had HCV (56 ± 14 years; 47% male; 18% advanced fibrosis; 47% MASLD). HBV with/without MASLD were similar in age, sex, and noncardiometabolic comorbidities (all p > 0.05) but those with MASLD had more advanced fibrosis ( p < 0.01) and significantly lower PRO scores: FACIT‐F Physical Well‐Being and Fatigue domains and all CLDQ (all p < 0.01) especially Fatigue domain (6% reduction in score range). HCV patients with MASLD were younger, more frequently female ( p < 0.01) with similar rates of advanced fibrosis, biopsy‐proven cirrhosis, and noncardiometabolic comorbidities (all p > 0.05). They had significantly lower scores in FACIT‐F Physical Well‐Being and all CLDQ domains (all p < 0.01); the greatest impairment was in Systemic Symptoms and Worry domains (6% reduction in score range). MASLD was independently associated with lower CLDQ scores in multivariate analysis ( p < 0.05).

Conclusions

Approximately half of HBV or HCV patients had MASLD and reported significantly worse PROs, highlighting the importance of proactive metabolic assessment and management in patients with chronic viral hepatitis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Patient Reported Outcome MeasuresHepatitis B, ChronicHepatitis C, ChronicFatty LiverHumansMaleFemaleMiddle AgedCross-Sectional StudiesAdultSurveys and QuestionnairesFatigueComorbidityCardiometabolic Risk FactorsAged

Stichwörter der Autor:innen

CLDQHRQLfatiguesystemic symptomswork productivityworry

Autor:innen und Institutionen

  • The Global NASH/MASH and Global Liver Councils, Washington, DC, USA.
  • 1st Department of Gastroenterology, National/Kapodistrian University of Athens, Athens, Greece.
  • Vall d'Hebron University Hospital, Barcelona, Spain.
  • Department of Gastroenterology, School of Medicine, Recep Tayyip Erdoğan University, Rize, Türkiye.
  • Center of Excellence for Metabolic Associated Fatty Liver Disease, National Sun Yat-Sen University, Kaohsiung, Taiwan.
  • Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital and Center of Metabolic Disorders and Obesity, Kaohsiung Medical University, Kaohsiung, Taiwan.

ORCID-Profile: Yusuf Yilmaz, Ming-Lung Yu, Mohamed El-Kassas, Khalid Alswat, Marlen Ivon Castellanos Fernandez, Yuichiro Eguchi, Caglayan Keklikkiran, Saeed Hamid, Stuart C Gordon, Ashwani K Singal, Linda Henry, Zobair M Younossi

Förderung

  • The Center for Outcomes Research for Liver Disease
  • Global NASH/MASH Council

Zitieren

APA

Papatheodoridis, G., Buti, M., Yilmaz, Y., Yu, M. L., El-Kassas, M., Alswat, K., Fernandez, M. I. C., Eguchi, Y., Duseja, A., Keklikkiran, C., Hamid, S., Chan, W. K., Gordon, S. C., Roberts, S. K., George, J., Singal, A. K., Ahmed, A., Lam, B., Nader, F., …, & Younossi, Z. M. (2026). Chronic Viral Hepatitis With MASLD: Implications for Clinical and Patient‐Reported Outcomes. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/jgh.70533

Vancouver

Papatheodoridis G, Buti M, Yilmaz Y, Yu ML, El-Kassas M, Alswat K, et al. Chronic Viral Hepatitis With MASLD: Implications for Clinical and Patient‐Reported Outcomes. Journal of Gastroenterology and Hepatology. 2026. doi:10.1111/jgh.70533

BibTeX
@article{Papatheodoridis2026,
  author = {Papatheodoridis, George and Buti, Maria and Yilmaz, Yusuf and Yu, Ming-Lung and El-Kassas, Mohamed and Alswat, Khalid and Fernandez, Marlen Ivon Castellanos and Eguchi, Yuichiro and Duseja, Ajay and Keklikkiran, Caglayan and Hamid, Saeed and Chan, Wah Kheong and Gordon, Stuart C and Roberts, Stuart K and George, Jacob and Singal, Ashwani K and Ahmed, Aijaz and Lam, Brian and Nader, Fatema and Henry, Linda and Stepanova, Maria and Alqahtani, Saleh A and Younossi, Zobair M},
  title = {Chronic Viral Hepatitis With MASLD: Implications for Clinical and Patient‐Reported Outcomes},
  journal = {Journal of Gastroenterology and Hepatology},
  year = {2026},
  doi = {10.1111/jgh.70533}
}
Kostenlos starten →